- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04565392
Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19) (Pepcid4COV19)
December 4, 2021 updated by: drpykessupplements.com
Proof-of-concept Randomized Placebo-controlled Trial of Famotidine for Outpatients With COVID-19
Kit for reading vital signs (thermometer, wrist blood pressure device, finger oximeter) and with study drug is overnighted to qualified subjects with early symptoms of COVID-19.
Subjects take a 20-milligram (mg) tab of famotidine or matching placebo twice a day, increase to 1 tablet every 8 hours if not better the 2nd day, and continue same for 30 days.
Vital signs, symptoms, compliance etc are rechecked daily for the 30 days and once again 60 days after starting study drug.
Consent, baseline, and follow-up are handled via internet plus calls/texts/virtual visits from study nurse or doctor as needed for clarifications and compliance.
Study Overview
Detailed Description
If an Over-The-Counter (OTC) medication could prevent worsening and hospitalization for COVID-19, it could stop the devastation wrought by the pandemic, and do so at a low cost.
One OTC medication has a pre-clinical and clinical rationale to help: famotidine.
For this study, 150 subjects are randomly assigned 50:50 to blinded treatment with 1 (20-milligram) tablet famotidine or matching placebo twice a day and can increase to 1 tablet three times a day.
This internet-driven study requires subjects to maintain contact with and follow advice of their local MD, so it does not increase their risks from the disease.
Baseline eligibility checklist follows informed consent.
Subjects must have at least 5 of the standard symptoms of COVID19, be willing to keep taking study medicine and reporting results daily for 30 days, must start within the first 6 days of symptoms, and must have a study partner to complete their follow-up in case they become unable.
The rate of subjects worsening or getting hospitalized is the main outcome measure.
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Fairfield, Connecticut, United States, 06812
- Pykonsult headquarters
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- - Probable COVID-19 based on presence of at least 5 of the following symptoms of acute onset within the prior 4 days: fever, cough, sore throat, fatigue, episodic chest pain or shortness of breath with exercise, muscle or body aches, headache, loss of smell or taste, stuffy or runny nose, chills or shivering, feeling hot or feverish, nausea, diarrhea
- - Subjects must signify that they have contacted a doctor about their current symptoms.
- - Subject gives informed consent for study and is willing to take the treatments and complete the scheduled evaluations.
- - Subject has acquired a study partner who has agreed to complete the follow-up forms for the subject if the subject unable or has been hospitalized.
Exclusion Criteria:
- - Constant rather than episodic trouble breathing, Persistent pain or pressure in the chest, New confusion, Inability to wake or stay awake, Bluish lips or face, or any other severe symptom [symptoms CDC urges immediate medical care for].
- - Known sensitivity or intolerance to famotidine or another acid-blocking drug.
- - Lack of access to the internet at home.
- - Using tizanidine (Zanaflex® , a muscle relaxant), dasatinib (Sprycel®, a drug for leukemia), cefditoren (Pivoxil®, an antibiotic), or fosamprenavir or delavirdine (drugs for HIV) [Drug exclusions are per US label for Pepcid].
- - Significant heart or kidney disease in the last 3 months according to subject's primary doctor
- - Pregnant women
- - Taking any investigational medications to treat COVID-19, famotidine, anti-viral drugs or corticosteroids and not stopping them within 48 hours before starting study treatment.
NOTE: patients are allowed to take over-the-counter agents for temporary relief of symptoms such as antipyretics and analgesics (aspirin, ibuprofen etc), cough remedies, anti-diarrheals, etc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: famotidine
A 20-milligram tablet of Pepcid in the morning and evening the first day, to be increased thereafter to one tablet every 8 hours if not improving
|
1 tablet every 12 hours and increase to 1 tablet every 8 hours if not improved by the second day of treatment
Other Names:
|
Placebo Comparator: Placebo
A placebo tablet to match a 20-milligram (mg) tablet of Pepcid in the morning and evening the first day, to be increased thereafter to one tablet every 8 hours if not improving
|
1 tablet every 12 hours and increase to 1 tablet every 8 hours if not improved by the second day of treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Course Binary Outcome
Time Frame: 30th (last) day of treatment, or if discontinues treatment early, last observation carried forward
|
Proportion of patients who self-rate as 6 on Patients Global Impression or are hospitalized for COVID-19 or similar symptoms or seek medical help for worsening symptoms, or get short of breath and have oxygen saturation below 90%, or die of COVID-19
|
30th (last) day of treatment, or if discontinues treatment early, last observation carried forward
|
Serious Adverse Events
Time Frame: 30th (last) day of treatment, or if discontinues treatment early, last observation carried forward]
|
Proportion of patients who report a serious adverse event, i.e., one that causes hospitalization or death
|
30th (last) day of treatment, or if discontinues treatment early, last observation carried forward]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to symptomatic recovery
Time Frame: There is no baseline rating. Outcome is rated on the 30th (last) day of treatment, or if discontinues treatment early, last observation carried forward
|
Proportion who answer the daily Global Recovery Question affirmatively: "Have you returned to your usual health (before your COVID-19 illness)?
yes/no" if verified on the same day's evaluation by at least one category of improvement in each of the symptoms endorsed at baseline on the SCL18 (see Outcome 4).
|
There is no baseline rating. Outcome is rated on the 30th (last) day of treatment, or if discontinues treatment early, last observation carried forward
|
SCL18 (self-check list of 18 symptoms of COVID-19)
Time Frame: Change from baseline at 30th (last) day of treatment, or if discontinues treatment early, last observation carried forward
|
a) mean change in total (18-item) score since baseline; b) proportion self-rating each item (symptom) at a lower or 0 intensity value than at baseline; c) subtotal on: Major Acute Physical Symptoms (SCL18 #2, Pains in heart or chest, #4 Nausea, vomiting or upset stomach, #6 Sore throat, #7 Cough, #9 Chills or shivering, #11 Diarrhea, or #13, Trouble getting your breath), d) physical symptoms (first 13 items of SCL18), f) cognitive symptoms (last 5 items of SCL18).
Each item is rated as (0) not at all, (1) a little bit (2) moderately, (3) quite a bit, or (4) extremely
|
Change from baseline at 30th (last) day of treatment, or if discontinues treatment early, last observation carried forward
|
Patient's Global Impression of Change
Time Frame: There is no rating at baseline. Outcome is for the 30th (last) day of treatment, or if discontinues treatment early, last observation carried forward
|
Proportions rating Patient's Global Impression of Change: as 1-4; as 1-3; as 1-2; as 6 (answer set: 1, very much improved, 2/much improved, 3/moderately improved, 4/minimally improved, 5/about the same, 6/worse)
|
There is no rating at baseline. Outcome is for the 30th (last) day of treatment, or if discontinues treatment early, last observation carried forward
|
Adverse Events
Time Frame: 30th (last) day of treatment, or if discontinues treatment early, last observation carried forward
|
Proportions of patients reporting new or worsening symptoms: a) any adverse event; b) the expected adverse events for famotidine (headache, dizziness, constipation, diarrhea); c) other adverse events, grouped by type
|
30th (last) day of treatment, or if discontinues treatment early, last observation carried forward
|
Day-60 Follow-up
Time Frame: 60 days after the start of treatment
|
Each of the same endpoints as above but evaluated 30 days after the end of treatment
|
60 days after the start of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Robert E Pyke, MD, PhD, Pykonsult LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 1, 2021
Primary Completion (Anticipated)
November 1, 2021
Study Completion (Anticipated)
January 31, 2022
Study Registration Dates
First Submitted
September 21, 2020
First Submitted That Met QC Criteria
September 21, 2020
First Posted (Actual)
September 25, 2020
Study Record Updates
Last Update Posted (Actual)
December 20, 2021
Last Update Submitted That Met QC Criteria
December 4, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Histamine Antagonists
- Histamine Agents
- Histamine H2 Antagonists
- Famotidine
Other Study ID Numbers
- Pykonsult 201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Famotidine 20 milligram tablet
-
Boehringer IngelheimCompleted
-
University of North Carolina, Chapel HillEli Lilly and CompanyRecruitingLichen Planus, Oral | Oral Lichen Planus | Lichen Planus, MucosalUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Radboud University Medical Center; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingLiver Diseases | Hepatic Encephalopathy | Portal Hypertension | Cirrhosis, Liver | Pathological ProcessesNetherlands, Belgium
-
BayerCompletedPharmacokineticsGermany
-
Janssen Research & Development, LLCCompleted
-
University of NottinghamSanofiRecruiting
-
University of Erlangen-Nürnberg Medical SchoolBayerRecruiting
-
University Medical Centre LjubljanaRecruiting
-
Pharmaceutical Research Unit, JordanCompleted
-
Sahlgrenska University Hospital, SwedenCalmino group ABCompleted